#### **Monitoring For Rotavirus Serotypes In The Americas**

#### **Jon Gentsch**

Centers for Disease Control and Prevention, Atlanta, USA

\* The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC).







PAHO/WHO Collaborating Center for Rotavirus and Other Viral Agents of Gastroenteritis

## Introduction

 Rationale for rotavirus strain surveillance
 Introduction to serotypes
 Surveillance in the Americas
 Conclusions and future directions



### Rotavirus Strain Surveillance in Vaccine Era


#### **Vaccine Research**

- Impact of vaccines on strain prevalence and evolution
  - Will immune selection over time result in emergence of strains that escape protection?
- Vaccine stability
  - Reversion to virulence
  - Transmission, gastroenteritis in unvaccinated
  - Reassortment with wild-type rotavirus

#### **Virus Evolution**

- > origin of new strains through reassortment
  - Role of animal rotaviruses
- > genetic variation in RV genes

## Rotavirus Serotype Classification



Provided by MK Estes

P type G type





### Methods: Processing Stool Samples for Strain Surveillance

Rotavirus Detection (e.g., IDEIA (Oxoid [Ely])

Genotype positives using hemi-nested RT-PCR

Identify genotypes by electrophoresis








### Human Rotavirus Serotypes and Genotypes


- Four historically common strains globally (>30 yrs)
- P[8]G9 emerged since 1995
  - Emerged since 2000



#### Data of K Banyai, PG types 2004-2008

Uncommon rotavirus genotypes: >20 G types, >30 P types and ~80 G-P combinations in humans

> Uncommon G & P types G5-P[6], [8] G6-P[6], [9] &[14] G8-P[1], [14] G10-P[9], [11] & [14] G12-P[6, [8] G3-P[11], [14] Occasionally some are regionally important



## Rotavirus Serotypes: Lessons learned from surveillance

Only few globally common strains
Periodic emerging strains
Huge diversity
Large temporal and geographic variation

## Surveillance in the United States

 National Rotavirus Strain Surveillance System (NRSSS)

New Vaccine Surveillance Network (NVSN)








PAHO/WHO Collaborating Center for Rotavirus and Other Viral Agents of Gastroenteritis National Rotavirus Strain Surveillance System (United States, 1996-2008)




#### Number of Positive and Total Rotavirus Tests, United States, 2000-2008, 33 Continuously Reporting Labs

RotaTeq introduced




### Longitudinal Variation of Rotavirus G Types in the United States (1996-2008)

RotaTeq introduced




# Geographical Serotype Variation USA (2007-2008)




Hull, Teel et al, in prep

## P and G Genotypes of Rotavirus Strains in United States (NRSSS)



Genotyping by sequencing identified a major outbreak of genotype G12 in the United States (primers for G12 are not routinely present in multiplex RT-PCR)




#### From Payne et al, PIDJ, 2009

## Surveillance in Latin America and the Caribbean


- Set up starting 2004 to assess disease burden and strains
- Strains received from rotavirus sentinel hospital surveillance network 2005-2007 analyzed at CDC
- Genotyping results from seven sites

#### Map of Countries Participating in the Rotavirus Surveillance Network in Latin America and the Caribbean




L Oliveira et al, JID 2009

### Strains Circulating in Seven Latin American Countries (2005-2007)



# Regional Variation of Strains Circulating in the Latin American (2005-2007)



### Are Vaccination Programs Impacting Prevalence of Common Strains?


 Vaccination of populations with Rotarix

 Increased prevalence of P[4]G2 (Brazil, Australia)

 Vaccination with RotaTeq


 Increased prevalence of P[8]G3 (Australia, United States)

### Temporal Variation in Predominant Strain, Central America



RotaTeq Vaccinated Population and increased P[8]G3

#### Rotavirus Genotypes in Nicaragua, 2007-2008



N=262, Patel et al, JAMA 2009

## Conclusions and Future Directions

- No convincing evidence for immune selection, more likely natural variation
  - Increasing prevalence P[4]G2, P[8]G3 in countries that have not adopted vaccines
- Supported by continued moderately high field efficacy of Rotarix vs P[4]G2 (e.g., Brazil, Australia [Snelling 2009, Nakagomi 2009], RotaTeq vs P[8]G3 [e.g., Boom et al 2008])
- Long term effectiveness studies where serotype specific VE and overall disease trends can be assessed
  - Needed to discriminate observed trends from natural strain fluctuations, emergence of new strains etc

#### <u>CDC</u>

Umesh Parashar Margaret Cortese Manish Patel Dan Payne Jackie Tate Jazmin Vojdani Tara Kerin Mathew Esona Mike Bowen

#### <u>PAHO</u>

Lucia Helena de Oliveira M. Carolina Danovaro-Holliday Jon Kim Andrus Ana Maria Bispo de Fillipis Cuauhtemoc Ruiz Matus

Epidemiological Surveillance of Ministries of Health from countries

Members of the NVSN and NRSSS networks in the United States